For the year ending 2025-12-31, CLNN made $200K in revenue. -$26,072K in net income. Net profit margin of -13036.00%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 200 | 342 | ||
| Cost of revenue | 43 | 70 | ||
| Research and development | 14,011 | 20,058 | ||
| General and administrative | 9,229 | 13,307 | ||
| Total operating expenses | 23,283 | 33,435 | ||
| Loss from operations | -23,083 | -33,093 | ||
| Interest income | 223 | 865 | ||
| Interest expense | 2,682 | 4,064 | ||
| Loss on extinguishment of notes payable | 0 | -214 | ||
| Issuance costs for common stock warrant liabilities | 0 | 157 | ||
| Loss on initial issuance of equity | 0 | -2,097 | ||
| Change in fair value of common stock warrant liabilities | 522 | 702 | ||
| Change in fair value of derivative liabilities | -363 | -379 | ||
| Change in fair value of clene nanomedicine contingent earn-out liability | 0 | 75 | ||
| Change in fair value of initial stockholders contingent earn-out liability | 0 | 10 | ||
| Research and development tax credits and unrestricted grants | 254 | 357 | ||
| Other expense, net | 0 | -1 | ||
| Total other income (expense), net | -3,090 | -6,307 | ||
| Net loss before income taxes | -26,173 | -39,400 | ||
| Income tax expense | 0 | 0 | ||
| Net loss | -26,173 | -39,400 | ||
| Unrealized loss on available-for-sale securities | 0 | - | ||
| Foreign currency translation adjustments | 101 | -127 | ||
| Unrealized gain (loss) on available-for-sale securities | - | -1 | ||
| Total other comprehensive income (loss) | 101 | -128 | ||
| Comprehensive loss | -26,072 | -39,528 | ||
| Basic EPS | -2.65 | -5.67 | ||
| Basic Average Shares | 9,858,907 | 6,954,133 | ||
Clene Inc. (CLNN)
Clene Inc. (CLNN)